ORLANDO, FL, USA (UroToday.com) - The group from Germany investigated the association of Gleason score 6 pathology to development of metastatic castrate-resistant prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Patients participating in the COU-301 trial, AFFIRM trial, as well as patients with mCRPC from the group’s outpatient clinic were retrospectively evaluated. Clinical data was assessed for patients with confirmed mCRPC between 3/2007 to 10/2014.
Out of 605 screened patients, a total of 77 patients with confirmed mCRPC were identified. Distribution of Gleason scores for Gleason 6, 7, 8, 9, and 10 were 2, 24, 28, 18, and 5 patients, respectively. Pathological whole prostate specimen obtained from radical prostatectomy was available in 43/77 patients. The remainder of patients either underwent androgen deprivation therapy only, systemic therapy, or radiation therapy. None of the two patients with Gleason score 6 with mCRPC underwent radical prostatectomy. One underwent brachytherapy and another had primary ADT. The authors hypothesize likely understaging at prostate biopsy in these 2 patients with Gleason score 6. Out of the confirmed final whole prostate pathology, none had Gleason score < 7.
A total of 29 patients died during follow-up. Gleason score at initial diagnosis was not a significant prognosticator for overall survival.
The group concluded a likely non significant occurrence of mCRPC during the development of prostate cancer for patients with Gleason pathology < 7. Nonetheless, patients with Gleason score 6 on prostate biopsy still need to be counseled about the probability of under-staging.
Presented by Christoph A. J. von Klot, Alena Boeker, Thomas R. W. Herrmann, Mario W. Kramer, Markus A. Kuczyk, and Axel S. Merseburger at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Department of Urology and Urologic Oncology, Medical School Hannover, Hannover, Germany; Hannover Medical School, Hannover, Germany; Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany
Reported by Mohammed Haseebuddin, MD, medical writer for UroToday.com